Compare TPVG & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPVG | LRMR |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.8M | 280.0M |
| IPO Year | N/A | 2014 |
| Metric | TPVG | LRMR |
|---|---|---|
| Price | $5.51 | $2.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $6.38 | ★ $16.50 |
| AVG Volume (30 Days) | 386.6K | ★ 976.0K |
| Earning Date | 01-01-0001 | 04-14-2026 |
| Dividend Yield | ★ 16.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.92 | N/A |
| P/E Ratio | $6.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.24 | $1.61 |
| 52 Week High | $8.20 | $5.37 |
| Indicator | TPVG | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 31.80 | 34.26 |
| Support Level | $5.37 | $1.77 |
| Resistance Level | $5.79 | $3.27 |
| Average True Range (ATR) | 0.17 | 0.22 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 6.38 | 11.17 |
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the operations of the firm function through the region of the United states.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.